Article
Mutation-Driven Therapy in MDS.
Current hematologic malignancy reports - 1 Dec 2019
Swoboda David M, Sallman David A
Abstract excerpt
PURPOSE OF REVIEW: Genetic sequencing in myelodysplastic syndrome (MDS) has provided an improved understanding of the complexity and heterozygosity of the disease. More importantly, our molecular understanding of MDS is leading to rapid advancements and personalized therapy for our patients. Herein, we review the current mutation-driven treatment landscape in MDS, first focusing on individual mutations. We then...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.